Status:
RECRUITING
Comparing Reticulocyte Hemoglobin and Transferrin Saturation to Guide Iron Treatment in People on Dialysis
Lead Sponsor:
King Chulalongkorn Memorial Hospital
Collaborating Sponsors:
Sysmex Asia Pacific
Center of Excellence for Metabolic Bone Disease in CKD patients, Faculty of Medicine, Chulalongkorn University
Conditions:
Hemodialysis
Anemia in End Stage Renal Disease
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
The goal of this clinical trial is to find out which method is better for guiding iron treatment in adult patients with end-stage kidney disease (ESKD) on hemodialysis who have anemia. The main quest...
Eligibility Criteria
Inclusion
- Adult (age 18-80 years)
- ESKD on chronic hemodialysis ≥ 6 months
- EPO therapy ≥ 6 months
- Hb \< 13.0 g/dL in male, \< 12.0 g/dL in female
Exclusion
- Serum ferritin \> 800 ng/mL or TSAT \> 40%
- Active infection or malignancy
- Hematologic disease including thalassemia major, hemolysis, myelofibrosis or myelodysplastic disease
- History of marrow suppressive or immunosuppressive medications in past 6 months
- History of active heart failure and recent myocardial infarction /stroke in past 6 months
- History of GI or external bleeding or receiving blood transfusion in past 6 months
Key Trial Info
Start Date :
January 31 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2025
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT06906835
Start Date
January 31 2025
End Date
September 30 2025
Last Update
April 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
King Chulalongkorn Memorial Hospital
Pathumwan, Bangkok, Thailand, 10330